Colgate-Palmolive Company (CL) Analysts See $0.79 EPS; Orleans Capital Management Decreased Medtronic (MDT) Stake By $1.71 Million

June 19, 2018 - By Russell Anderson

Medtronic plc (NYSE:MDT) Logo

Orleans Capital Management Corp decreased Medtronic Inc (MDT) stake by 69.81% reported in 2018Q1 SEC filing. Orleans Capital Management Corp sold 21,335 shares as Medtronic Inc (MDT)’s stock rose 4.71%. The Orleans Capital Management Corp holds 9,228 shares with $740,000 value, down from 30,563 last quarter. Medtronic Inc now has $116.80B valuation. The stock decreased 0.61% or $0.53 during the last trading session, reaching $86.25. About 3.00M shares traded. Medtronic plc (NYSE:MDT) has risen 0.84% since June 19, 2017 and is uptrending. It has underperformed by 11.73% the S&P500. Some Historical MDT News: ; 15/05/2018 – MEDTRONIC SAYS ADAPTIVCRT SHOWS IMPROVED PATIENT SURVIVAL; 23/04/2018 – MEDTRONIC IN.PACT(TM) ADMIRAL(TM) DRUG COATED BALLOON GETS FDA; 24/05/2018 – MEDTRONIC SEES FY ADJ EPS $5.10 TO $5.15, EST. $5.15; 23/04/2018 – ARCA BIOPHARMA & MEDTRONIC EXTEND GENCARO CLINICAL TRIAL PACT; 22/03/2018 – Global Transcatheter Aortic Valve lmplantation (TAVI) Market Analysis & Outlook 2018-2022 with Profiles of Abbott Laboratories, Boston Scientific, Edwards Lifesciences & Medtronic – ResearchAndMarkets; 01/05/2018 – Medtronic Announces TiONIC Technology, a Titanium 3D Printed Platform for Spine Surgery Implants; 17/04/2018 – MEDTRONIC EXPANDS FOCUS ON INTERVENTIONAL ONCOLOGY W/ U.S; 23/05/2018 – New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive Medication; 03/05/2018 – lntact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty lll (TOBA lll) Clinical Trial; 11/05/2018 – Medtronic Study Confirms Feasibility of New Extravascular Approach to ICD Therapy

Analysts expect Colgate-Palmolive Company (NYSE:CL) to report $0.79 EPS on July, 20.They anticipate $0.07 EPS change or 9.72% from last quarter’s $0.72 EPS. CL’s profit would be $689.14M giving it 20.03 P/E if the $0.79 EPS is correct. After having $0.74 EPS previously, Colgate-Palmolive Company’s analysts see 6.76% EPS growth. The stock decreased 2.19% or $1.42 during the last trading session, reaching $63.31. About 7.90M shares traded or 73.71% up from the average. Colgate-Palmolive Company (NYSE:CL) has declined 15.42% since June 19, 2017 and is downtrending. It has underperformed by 27.99% the S&P500. Some Historical CL News: ; 27/04/2018 – Colgate sales growth fails to shine; 22/05/2018 – P&G, Colgate and Clorox were last this cheap on a relative basis to the market seven to nine years ago; 07/03/2018 – Colgate Recommends Shareholders Reject “Mini-Tender” Offer By Baker Mills LLC; 19/03/2018 – COLGATE CONTINUES TO RECOMMEND HOLDERS REJECT “MINI-TENDER”; 04/05/2018 – COLGATE-PALMOLIVE CO – HICKEY WILL ASSUME ROLE OF VICE CHAIRMAN; 21/05/2018 – COLGATE-PALMOLIVE (INDIA) LTD COLG.NS – MARCH QTR NET PROFIT 1.89 BLN RUPEES VS PROFIT OF 1.43 BLN RUPEES LAST YEAR; 27/04/2018 – COLGATE-PALMOLIVE CO – PLANNING FOR A YEAR OF GROSS MARGIN EXPANSION AND EXPECT DOUBLE-DIGIT EARNINGS PER SHARE GROWTH IN 2018; 07/03/2018 – COLGATE REPORTS 5% DIV BOOST – EFFECTIVE 2Q 2018; 04/05/2018 – Subscribers: Disregard Colgate-Palmolive Earnings Headline; 21/05/2018 – COLGATE-PALMOLIVE (INDIA) LTD COLG.NS SAYS VOLUME GROWTH OF 4 PCT IN QTR

Among 27 analysts covering Colgate-Palmolive (NYSE:CL), 6 have Buy rating, 1 Sell and 20 Hold. Therefore 22% are positive. Colgate-Palmolive had 72 analyst reports since July 21, 2015 according to SRatingsIntel. Morgan Stanley downgraded the shares of CL in report on Monday, April 30 to “Hold” rating. As per Monday, January 18, the company rating was upgraded by BNP Paribas. Citigroup maintained it with “Buy” rating and $88 target in Friday, July 29 report. The rating was initiated by Atlantic Securities with “Overweight” on Wednesday, January 6. The rating was downgraded by RBC Capital Markets on Monday, January 4 to “Sector Perform”. The firm has “Buy” rating by Bank of America given on Monday, September 12. The firm has “Hold” rating by RBC Capital Markets given on Friday, March 24. The firm has “Outperform” rating given on Friday, January 15 by BNP Paribas. As per Wednesday, August 23, the company rating was maintained by KeyBanc Capital Markets. The stock of Colgate-Palmolive Company (NYSE:CL) earned “Neutral” rating by UBS on Friday, July 31.

Since January 9, 2018, it had 0 buys, and 24 sales for $42.83 million activity. MOISON FRANCK J also sold $10.02M worth of Colgate-Palmolive Company (NYSE:CL) on Monday, February 5. On Tuesday, February 20 HICKEY DENNIS J sold $396,561 worth of Colgate-Palmolive Company (NYSE:CL) or 5,651 shares. $399,530 worth of stock was sold by Marsili Daniel B on Tuesday, February 20. Shares for $292,026 were sold by Skala Justin. Deoras Mukul sold 2,572 shares worth $180,521. $972,125 worth of Colgate-Palmolive Company (NYSE:CL) was sold by HUSTON JOHN J on Friday, February 9. 7,000 shares valued at $435,600 were sold by Gayle Helene D on Thursday, May 10.

Investors sentiment decreased to 0.69 in Q1 2018. Its down 0.18, from 0.87 in 2017Q4. It is negative, as 71 investors sold Colgate-Palmolive Company shares while 487 reduced holdings. 72 funds opened positions while 313 raised stakes. 605.00 million shares or 0.22% less from 606.34 million shares in 2017Q4 were reported. Glenmede Na invested 0.3% in Colgate-Palmolive Company (NYSE:CL). Kentucky Retirement Systems Ins Tru Fund reported 0.28% stake. Los Angeles Capital Mgmt & Equity Rech has invested 0.04% in Colgate-Palmolive Company (NYSE:CL). Thompson Rubinstein Investment Or holds 1.49% in Colgate-Palmolive Company (NYSE:CL) or 61,044 shares. Cambridge Investment holds 0.07% or 92,585 shares. Raymond James Finance Advsrs has 0.08% invested in Colgate-Palmolive Company (NYSE:CL) for 199,306 shares. Moreover, Calamos Advisors Ltd Liability has 0.04% invested in Colgate-Palmolive Company (NYSE:CL). Barrett Asset Mngmt Limited Liability Com stated it has 0.07% in Colgate-Palmolive Company (NYSE:CL). Crawford Counsel reported 0.09% stake. Guyasuta Inv Advisors Inc owns 277,505 shares or 2.33% of their US portfolio. Campbell Newman Asset Management owns 13,521 shares. Smithfield Tru stated it has 22,191 shares. Parthenon Ltd Llc reported 0.53% in Colgate-Palmolive Company (NYSE:CL). Fruth Investment Management has invested 0.09% in Colgate-Palmolive Company (NYSE:CL). Toth Fincl Advisory Corp reported 68,198 shares stake.

Colgate-Palmolive Company, together with its subsidiaries, makes and sells consumer products worldwide. The company has market cap of $55.23 billion. It operates through two divisions, Oral, Personal and Home Care; and Pet Nutrition. It has a 26.84 P/E ratio. The firm offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other related products.

More important recent Colgate-Palmolive Company (NYSE:CL) news were published by: Streetinsider.com which released: “After-Hours Stock Movers 06/18: (GEVO) (VIVE) (CL) Higher; (PAGS) (TELL) (DEA) Lower (more…)” on June 18, 2018, also Investorplace.com published article titled: “10 Consumer Stocks on the Clearance Rack”, Seekingalpha.com published: “Colgate-Palmolive Offers An Attractive Entry Point” on May 30, 2018. More interesting news about Colgate-Palmolive Company (NYSE:CL) was released by: Gurufocus.com and their article: “Global Capital Markets Lower on Monday” with publication date: June 18, 2018.

Orleans Capital Management Corp increased Texas Instruments (NASDAQ:TXN) stake by 4,285 shares to 23,066 valued at $2.40 million in 2018Q1. It also upped Intel Corp (NASDAQ:INTC) stake by 15,380 shares and now owns 40,730 shares. Boeing Co (NYSE:BA) was raised too.

Analysts await Medtronic plc (NYSE:MDT) to report earnings on August, 28. They expect $1.13 EPS, up 0.89% or $0.01 from last year’s $1.12 per share. MDT’s profit will be $1.53 billion for 19.08 P/E if the $1.13 EPS becomes a reality. After $1.42 actual EPS reported by Medtronic plc for the previous quarter, Wall Street now forecasts -20.42% negative EPS growth.

Among 30 analysts covering Medtronic (NYSE:MDT), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Medtronic had 89 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 9 by Needham. The stock of Medtronic plc (NYSE:MDT) earned “Hold” rating by BTIG Research on Thursday, May 25. The stock of Medtronic plc (NYSE:MDT) earned “Neutral” rating by JP Morgan on Tuesday, January 3. As per Friday, November 13, the company rating was upgraded by Goldman Sachs. BMO Capital Markets maintained Medtronic plc (NYSE:MDT) rating on Wednesday, November 23. BMO Capital Markets has “Outperform” rating and $87 target. The firm earned “Buy” rating on Friday, August 26 by UBS. The stock has “Hold” rating by Stifel Nicolaus on Thursday, May 25. The firm has “Neutral” rating by Wedbush given on Wednesday, June 1. RBC Capital Markets maintained Medtronic plc (NYSE:MDT) on Wednesday, April 19 with “Buy” rating. The company was maintained on Thursday, February 22 by Citigroup.

Colgate-Palmolive Company (NYSE:CL) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>